Profs feel satisfied, snubbed by Nobel Prizes
The Nobel Prize was awarded Monday for cancer immunology. The 2018 Nobel laureates James Allison and Tasuku Honjo found proteins known as immune checkpoints that can stop T-cells, causing them to pass over a cancer cell instead of attacking it. Checkpoint inhibitors drastically transformed the field of cancer immunology said Mario Sznol, co-director of the Cancer Immunology Program at YCC. He praised the decision to award Allison and Honjo, but said many others also deserved recognition. “One who didn’t get the Nobel Prize but made a major, major contribution to understanding this pathway and its role in the treatment of cancer is Dr. Lieping Chen, who’s here at Yale, and as far as I’m concerned, Dr. Chen also deserves part of the Nobel Prize.”
Lieping Chen, PhD, wins prestigious 2017 Warren Alpert Prize
Lieping Chen, Ph.D., co-director of the Cancer Immunology Program at Yale Cancer Center and United Technologies Corporation Professor in Cancer Research and professor of immunobiology, of dermatology and of medicine at Yale School of Medicine, has been presented with the 2017 Warren Alpert Foundation Prize for transformative discoveries in the field of cancer immunology.
Lieping Chen among five scientists recognized for discoveries in cancer immunology
Lieping Chen, Ph.D., the United Technologies Corporation Professor in Cancer Research and professor of immunobiology, of dermatology, and of medicine, is one of five scientists to receive the 2017 Warren Alpert Foundation Prize.
Innovation to Impact: Dr. Lieping Chen and NextCure
Dr. Lieping Chen is a pioneer in the field of immuno-oncology and his discoveries have led to life-saving drugs for cancer patients. Now, with the support of the Yale Office of Cooperative Research, Dr. Chen has launched a startup—NextCure—that is poised to lead to even more breakthrough treatments.
Central Nervous System Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear. Now, Yale researchers have identified a mechanism that offers this new insight into this protective effect. The findings were described in the April 8 journal of Science Advances.
New Germantown biotech nets $67 million from investors
New Germantown biotech nets $67 million from investors, including Eli Lilly and Pfizer to fund research and development in Dr. Lieping Chen’s laboratory. Immuno-oncology has attracted growing notice over the past few years, but only a handful of drugs in the nascent field have been approved for broad public use. Two of those drugs leading the charge — Keytruda and Opdivo — target the PD-1/PD-L1 pathway that Chen is credited with innovating. Keytruda, manufactured by Merck, made headlines last year when former president Jimmy Carter said he was using it to treat cancerous tumors in his brain and liver. Carter said in December that he is cancer-free.Source: The Washington Post
FDA approves new immunotherapy drug used at Yale Cancer Center for metastatic lung cancer
The FDA has approved an immunotherapy drug for patients with previously-treated advanced squamous non-small cell lung cancer (NSCLC). Nivolumab, used in multiple clinical trials at Yale Cancer Center for metastatic lung cancer and melanoma, is the only FDA-approved monotherapy in 15 years to demonstrate proven superior overall survival compared to standard of care for this type of cancer.
Tackling cancer with a new paradigm
In the 1980s, immunotherapy researcher Lieping Chen, M.D., Ph.D., embraced the career goal of curing one cancer. That lofty-seeming goal is beginning to look more modest today. Recent clinical trials have shown that one cancer after another is vulnerable to immune modulation therapy, a cancer-fighting strategy Chen pioneered that for years was considered marginal.
Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology
Winners of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology discuss their contributions to the discovery of the PD-1 immune checkpoint and its role in cancer immunotherapy. Featuring Lieping Chen, M.D., Ph.D., of Yale University School of Medicine. The William B. Coley Award is given annually to scientists who have made important contributions to basic or tumor immunology, and is the highest honor bestowed by the Cancer Research Institute.Source: Cancer Research Institute
United Technologies Endows Yale Cancer Center Professorship for Research
The fight against cancer in Connecticut is getting a major boost from United Technologies Corp. (NYSE: UTX), which has donated $3 million to establish a new endowed professorship at Yale Cancer Center (YCC) in New Haven, Conn.
Dr. Lieping Chen is named to the inaugural United Technologies Corporation endowed post
Dr. Lieping Chen, newly appointed as the United Technologies Corporation Professor in Cancer Research, focuses his research on developing new treatment options for cancer. His laboratory discovered the B7-H1/PD-1 immune inhibitory pathway and established the principle of cancer therapy by blocking this pathway.